Diaminopyrimidine benzenesulfone derivatives and uses thereof
US-2016332993-A1 · Nov 17, 2016 · US
Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
US11446309B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11446309-B2 |
| Application number | US-201415034922-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 7, 2014 |
| Priority date | Nov 8, 2013 |
| Publication date | Sep 20, 2022 |
| Grant date | Sep 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating diffuse large B-cell lymphoma (DLBCL) comprising: administering to a subject in need thereof a first agent, S-JQ35: or a pharmaceutically acceptable salt thereof, in combination with one or more second agents selected from ABT263, or ABT199, wherein the first agent and the one or more second agents are administered in an amount effective to treat the DLBCL. 2. The method of claim 1 , wherein the first agent and the one or more second agents are administered sequentially or simultaneously. 3. The method of claim 1 , wherein the subject is a mammal. 4. The method claim 3 , wherein the subject is a human patient. 5. The method of claim 1 , further comprising treating the subject with an additional anti-neoplasia therapy. 6. The method of claim 5 , wherein the additional anti-neoplasia therapy is surgery, radiation therapy, chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, adjuvant therapy, immunotherapy or a combination thereof.
Assignees
Inventors
Classifications
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine · CPC title
- A61K31/551Primary
having two nitrogen atoms, e.g. dilazep · CPC title
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11446309B2 cover?
- The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
- Who is the assignee on this patent?
- Dana Farber Cancer Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/551. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).